Abstract:CD147 also known as EMMPRIN, basigin, and HAb18G, is a single-chain type I transmembrane protein shown to be overexpressed in aggressive human cancers of CNS, head and neck, breasts, lungs, gastrointestinal, genitourinary, skin, hematological, and musculoskeletal. In these malignancies, the molecule is integral to the diverse but complimentary hallmarks of cancer: it is pivotal in cancerous proliferative signaling, growth propagation, cellular survival, replicative immortality, angiogenesis, metabolic reprogramming, immune evasion, invasion, and metastasis. CD147 also has regulatory functions in cancer-enabling characteristics such as DNA damage response (DDR) and immune evasion. These neoplastic functions of CD147 are executed through numerous and sometimes overlapping molecular pathways: it transduces signals from upstream molecules or ligands such as cyclophilin A (CyPA), CD98, and S100A9; activates a repertoire of downstream molecules and pathways including matrix metalloproteinases (MMPs)-2,3,9, hypoxia-inducible factors (HIF)-1/2α, PI3K/Akt/mTOR/HIF-1α, and ATM/ATR/p53; and also functions as an indispensable chaperone or regulator to monocarboxylate, fatty acid, and amino acid transporters. Interestingly, induced loss of functions to CD147 prevents and reverses the acquired hallmarks of cancer in neoplastic diseases. Silencing of Cd147 also alleviates known resistance to chemoradiotherapy exhibited by malignant tumors like carcinomas of the breast, lung, pancreas, liver, gastric, colon, ovary, cervix, prostate, urinary bladder, glioblastoma, and melanoma. Targeting CD147 antigen in chimeric and induced-chimeric antigen T cell or antibody therapies is also shown to be safer and more effective. Moreover, incorporating anti-CD147 monoclonal antibodies in chemoradiotherapy, oncolytic viral therapy, and oncolytic virus-based-gene therapies increases effectiveness and reduces on and off-target toxicity. This study advocates the expedition and expansion by further exploiting the evidence acquired from the experimental studies that modulate CD147 functions in hallmarks of cancer and cancer-enabling features and strive to translate them into clinical practice to alleviate the emergency and propagation of cancer, as well as the associated clinical and social consequences.

Targeted degradation of CD147 proteins in melanoma

Chemical proteomics reveal CD147 as a functional target of pseudolaric acid B in human cancer cells

Synthesis and Evaluation of a Novel Small-molecule Compound As an Anticancer Inhibitor of CD147.

Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy

CD147 interacts with NDUFS6 in regulating mitochondrial complex I activity and the mitochondrial apoptotic pathway in human malignant melanoma cells

A Small Interfering CD147-Targeting RNA Inhibited the Proliferation, Invasiveness, and Metastatic Activity of Malignant Melanoma

Targeting CD147 for T to NK Lineage Reprogramming and Tumor Therapy.

Potent and Preferential Degradation of CDK6 Via Proteolysis Targeting Chimera Degraders

Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

CD147-targeted Sirna in A375 Malignant Melanoma Cells Induces the Phosphorylation of EGFR and Downregulates Cdc25c and MEK Phosphorylation.

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

CD147: an integral and potential molecule to abrogate hallmarks of cancer

Versatile Nano‐PROTAC‐Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy

Proteome Analysis of Multidrug Resistance of Human Oral Squamous Carcinoma Cells Using Cd147 Silencing

PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review

Discovery of Novel PROTACs Based on Multi-Targeted Angiogenesis Inhibitors.

Depletion of CD147 Sensitizes Human Malignant Melanoma Cells to Hydrogen Peroxide-Induced Oxidative Stress.

Depletion of CD147 sensitizes human malignant melanoma cells to hydrogen peroxide-induced oxidative stress

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Design, Synthesis, and Biological Evaluation of Proteolysis-Targeting Chimeras as Highly Selective and Efficient Degraders of Extracellular Signal-Regulated Kinase 5